Novartis Pharma Services AG

Novartis Pharma Services AG is involved in clinical research centered on patients previously treated with CAR T-cell therapy, with attention to extended monitoring after treatment across multiple indications.

• CAR T-cell therapy follow-up
• Post-treatment patient monitoring
• Delayed adverse effects

The research focus includes ongoing observation of individuals from different disease backgrounds who have received Novartis or Penn CAR T-cell treatment.